# Study Of Eribulin (E7389) In Patients With Advanced Solid Tumors And Normal Or Reduced Hepatic Function As Per Child-Pugh System

> **NCT00706095** · PHASE1 · COMPLETED · sponsor: **Eisai Inc.** · enrollment: 18 (actual)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** E7389
- **DRUG:** E7389
- **DRUG:** E7389

## Key facts

- **NCT ID:** NCT00706095
- **Lead sponsor:** Eisai Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-02
- **Primary completion:** 2009-09
- **Final completion:** 2010-04
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2012-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00706095

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00706095, "Study Of Eribulin (E7389) In Patients With Advanced Solid Tumors And Normal Or Reduced Hepatic Function As Per Child-Pugh System". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00706095. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*